Industry leaders in large-scale flowthrough
PeptiSystems team has over 100 years of combined experience working in this field. Our CEO, Lars Holmberg, was in charge of the innovation and development of the industry's first large-scale flowthrough column technology instruments for oligonucleotide synthesis in the 1980s and 1990s at Pharmacia, Amersham and later at GE Healthcare. Working together, the PeptiSystems team has taken flowthrough column technology to a new level and applied it also to work successfully for large-scale peptide synthesis for the first time in the industry.
The PeptiSystems co-founders worked together for 4 years at GE Healthcare to develop a peptide synthesizer based on flowthrough column technology. However, that project was cancelled due to reorganisation in the company. A year later, the team decided to start PeptiSystems to realize the innovation and make an impact on the way both peptides and oligonucleotides are synthesized today.
Meet our team
Chief Executive Officer
Karin has 20+ years' experience from different leadership positions within the MedTech industry. She has a broad background from product development, product management and business operations.
Before joining PeptiSystems, Karin had the overall business responsibility as General Manager for a subdivision within GE Healthcare's Molecular Imaging segment.
She has a PhD position in Solid State electronics from Uppsala University.
Chief Scientific Officer
Lars invented the first large-scale flowthrough column technology instruments for oligonucleotide synthesis while at Pharmacia in the 1990s. He worked for GE Healthcare commercialising the instruments for many years until starting PeptiSystems in 2014. He has a Ph.D. in Carbohydrate Chemistry
VP of Software
Mats has a M.Sc. in Computer Sciences and over 30 years of experience in the software industry. He worked over 10 years at GEHC as a systems architect, project manager and specialist in the development of UNICORN, the software used at GEHC for their oligonucleotide manufacturing instruments.
VP of Hardware
Rannar has over 30 years of experience in R&D of peptide chemistry, synthesis, biochemistry, and pharmacology. He was head of the R&D of the PeptiPilot Instruments at GEHC. He has a publication record of over 80 research articles in peer-reviewed scientific journals, book chapters and several patents/patent applications. Rannar has a Ph.D. in Biological Chemistry, and qualification of Associate Professor in Medical Biochemistry at Karolinska Institute. He has previously co-founded companies in Life Sciences.
Ulf has 25+ years in the life science areas and worked for 15 years at GEHC in R&D, project management, and product support. He is a specialist in polymer supports, oligonucleotide and peptide synthesis and biomolecule conjugate synthesis. Ulf has 7 patents/patent applications, published >20 scientific publications in peer reviewed journals and one book chapter. Ulf has a Ph.D. in Oligosaccharide Synthesis.
Global Product Support Manager
Łukasz completed his Ph.D. in Peptide Chemistry in 2006 at the Faculty of Chemistry, University of Warsaw, Poland. He held multiple PostDoc positions in Brussels, Belgium, and Dublin, Ireland, working with companies on different projects related to the synthesis of peptide therapeutics. He then moved to the industry and worked as the Head of Peptide Libraries and R&D Manager for GENEPEP and later as the Product Manager for Gyros Protein Technologies. His goal is to combine his knowledge of Peptide Synthesis and interest in technology and apply it in the creation of better peptide synthesizers.
Victoriia has completed Ph.D. in 2010 in the field of peptide chemistry and antibiotic modification. She did research in Germany, USA, Russia and Sweden, mostly specialized in the field of in situ and in vitro peptide synthesis. She has wide experience in the life sciences areas.
Meet Our Investors
ALMI Invest is the largest early-stage investment company in Sweden, owned by the Swedish State. Allan Asp represents ALMI Invest on PeptiSystems board of directors.
PÄAB is a privately owned business angel investment fund that focuses on early stage startups in technology and life sciences. Mats Johnson represents PÄAB on PeptiSystems board of directors and is the former CEO of Bio-Works (listed company).
Peter Ehrenheim is the former CEO of the Life Sciences division at GE Healthcare and has invested in PeptiSystems.